Last reviewed · How we verify
Erythropoietin alfa
Erythropoietin alfa is a Erythropoiesis-stimulating agent (ESA) Biologic drug developed by Bio Sidus SA. It is currently in Phase 3 development for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients with HIV infection. Also known as: procrit, epoetin alfa, Nanokine, Eprex, Espogen (LG Life Science Ltd.).
Erythropoietin alfa is a recombinant human erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
Erythropoietin alfa is a recombinant human erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients with HIV infection.
At a glance
| Generic name | Erythropoietin alfa |
|---|---|
| Also known as | procrit, epoetin alfa, Nanokine, Eprex, Espogen (LG Life Science Ltd.) |
| Sponsor | Bio Sidus SA |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Biologic |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Erythropoietin alfa mimics the natural hormone erythropoietin, which regulates red blood cell production in response to tissue hypoxia. By binding to EPO receptors on erythroid progenitor and precursor cells in the bone marrow, it promotes their proliferation, differentiation, and maturation into mature red blood cells. This increases hemoglobin levels and oxygen-carrying capacity of the blood.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with cancer receiving chemotherapy
- Anemia in patients with HIV infection
Common side effects
- Hypertension
- Thrombotic events (deep vein thrombosis, pulmonary embolism)
- Headache
- Fever
- Injection site reactions
Key clinical trials
- A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (PHASE3)
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (PHASE3)
- Vafseo Outcomes In-Center Experience (PHASE3)
- A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (PHASE3)
- Choices About Genetic Testing And Learning Your Risk With Smart Technology (NA)
- Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erythropoietin alfa CI brief — competitive landscape report
- Erythropoietin alfa updates RSS · CI watch RSS
- Bio Sidus SA portfolio CI
Frequently asked questions about Erythropoietin alfa
What is Erythropoietin alfa?
How does Erythropoietin alfa work?
What is Erythropoietin alfa used for?
Who makes Erythropoietin alfa?
Is Erythropoietin alfa also known as anything else?
What drug class is Erythropoietin alfa in?
What development phase is Erythropoietin alfa in?
What are the side effects of Erythropoietin alfa?
What does Erythropoietin alfa target?
Related
- Drug class: All Erythropoiesis-stimulating agent (ESA) drugs
- Target: All drugs targeting Erythropoietin receptor (EPOR)
- Manufacturer: Bio Sidus SA — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Anemia associated with chronic kidney disease
- Indication: Drugs for Anemia in patients with cancer receiving chemotherapy
- Indication: Drugs for Anemia in patients with HIV infection
- Also known as: procrit, epoetin alfa, Nanokine, Eprex, Espogen (LG Life Science Ltd.)
- Compare: Erythropoietin alfa vs similar drugs
- Pricing: Erythropoietin alfa cost, discount & access